Heartburn in Patients with Gastro-Oesophageal Reflux Disease in Germany and Sweden: A Study on Patients' Burden of Disease

PharmacoEconomics

Volumn 21, Issue 15, 2003, Pages 1091-1102

  Jones, Roger ^a   Horbach, Silke ^b   Sander, Peter ^b   Rydén Bergsten, Tina ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ALTANA PHARMA AG   (Germany)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; BURDEN OF DISEASE; DISEASE DURATION; DISEASE SEVERITY; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL SYMPTOM; GERMANY; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; SWEDEN;

ADOLESCENT; ADULT; AGED; COMORBIDITY; COST OF ILLNESS; FEMALE; GASTROESOPHAGEAL REFLUX; GERMANY; HEARTBURN; HUMANS; MALE; MIDDLE AGED; PROTON PUMPS; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SWEDEN;

EID: 0142217264     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200321150-00003     Document Type: Article

References (37)

1. Sontag SJ. Defining GERD. Yale J Biol Med 1999; 72: 69-80
2. Katz PO. Gastroesophageal reflux disease. J Am Geriatr Soc 1998; 46: 1558-65
3. Green JA, Amaro R, Barkin JS. Just a little heartburn? Am J Gastroenterol 2000; 95: 813-4
4. Lagergren J, Bergström R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-31
5. Valle C, Broglia F, Pistorio A, et al. Prevalence and impact of symptoms suggestive of gastroesophageal reflux disease. Dig Dis Sci 1999; 44: 1848-52
6. Ruth J, Mansson I, Sandberg N. The prevalence of symptoms of esophageal disorders. Scand J Gastroenterol 1991; 26: 73-81
7. Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux incidence and precipitating factors. Am J Dig Dis 1976; 21: 953-6
8. Sonnenberg A, El-Serag HB. Clinical epidemiology and natural history of gastroesophageal reflux disease. Yale J Biol Med 1999; 72: 81-92
9. Vallot T, Bruley des Varannes S, Grimaud JC, et al. Epidémiologie du reflux gastro-oesophagien en médicine générale. Gastroenterol Clin Biol 1999; 23: 1139-44
10. Kennedy T, Jones R. The prevalence of gastro-oesophageal reflux symptoms in a UK population and the consultation behaviour of patients with these symptoms. Aliment Pharmacol Ther 2000; 14: 1589-94
11. Glise H. Quality of life and cost of therapy in reflux disease. Scand J Gastroenterol 1995; 30 Suppl. 210: 38-42
12. Locke GR, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population based study in Olmsted County Minnesota. Gastroenterology 1997; 112: 1448-56
13. Dent J, Brun J, Fendrick AM, on behalf of the Genval Workshop Group., et al. An evidence-based appraisal of reflux disease management: the Genval Workshop Report. Gut 1999; 44 Suppl. 2: S1-S16
14. O'Connor JB, Provenzale D, Brazer S. Economic considerations in the treatment of gastroesophageal reflux disease: a review. Am J Gastroenterol 2000; 95: 3356-64
15. Heading RC. Aims in the management of gastroesophageal reflux disease: a gastroenterologist's viewpoint. Dis Esophagus 1999; 12: 1-6
16. Scott M, Gelhot AR. Gastroesophageal reflux disease: diagnosis and management. Am Fam Phys 1999; 59: 1161-9
17. Enck P, Dubois D, Marquis P. Quality of life in patients with upper gastrointestinal symptoms: results from the Domestic/ International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol Suppl 1999; 231: 48-54
18. Havelund T, Lind T, Wiklund I. Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. Am J Gastroenterol 1999; 94: 1782-9
19. EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208
20. Revicki DA, Wood M, Wiklund I, et al. Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease. Qual Life Res 1998; 7: 75-83
21. Dolan P, Gudex C, Kind P, et al. The time-trade-off method: results from a general population study. Health Econ 1996; 5: 141-54
22. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35: 1095-108
23. Rentz AM, Battista C, Trudeau E, et al. Symptom and health-related quality-of-life measures for use in selected gastrointestinal disease studies. Pharmacoeconomics 2001; 19: 349-63
24. Statistical analysis software, release 6.12. Cary (NC): SAS Institute Inc., 1989-1996
25. Euroqol EQ-5D user guide: a simple, generic measure validated in several countries measuring health for clinical and economic appraisal, supported by an international research group. Version B (1/98). Dordrecht: The EuroQol Foundation
26. Wiklund I, Glise H. Quality of life in different gastrointestinal conditions. Eur J Surg Suppl 1998; 582: 56-61
27. Myers C, Wilks D. Comparison of Euroqol EQ-5D and SF-36 in patients with chronic fatigue syndrome. Qual Life Res 1999; 8: 9-16
28. Greiner W, Graf von der Schulenburg JM, Bergmann KC. Lebensqualität von erwachsenen Asthmapatienten. Pneumologie 1999; 53: 283-8
29. Bardhan KD, Müller-Lissner S, Bigard MA, for the European Study Group, et al. Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. BMJ 1999; 318: 502-7
30. Fass R, Pulliam G, Johnson C, et al. Symptom severity and oesophageal chemosensitivity to acid in older and young patients with gastro-oesophageal reflux. Age Ageing 2000; 29: 125-30
31. Wilkins WE, Ridley MG, Pozniak AL. Benign stricture of the oesophagus: role on non-steroidal anti-inflammatory drugs. Gut 1984; 25: 478-80
32. Lanas A, Hirschowitz BI. Significant role of aspirin use in patients with esophagitis. J Clin Gastroenterol 1991; 13: 622-7
33. El-Serag HB, Sonnenberg A. Non-steroidal anti-inflammatory drugs represent risk factors of erosions and peptic strictures of the esophagus. Am J Gastroenterol 1997; 92: 57-60
34. Schindlbeck NE, Klauser AG, Berghammer G, et al. Three year follow up of patients with gastrooesophageal reflux disease. Gut 1992; 33: 1016-9
35. Sacher-Huvelin S, Gournay J, Amouretti M, et al. Esophage acido-sensible: histoire naturelle et retentissement sur la qualité de vie. Gastroenterol Clin Biol 2000; 24: 911-6
36. Agréus L. The epidemiology of functional gastrointestinal disorders. Eur J Surg Suppl 1998; 583: 60-6
37. Johansson KE, Ask P, Boeryd B, et al. Oesophagitis, signs of reflux, and gastric acid secretion in patients with symptoms of gastro-oesophageal reflux disease. Scand J Gastroenterol 1986; 21: 837-47